author-photo

Rodger Allen

UCB

24

Papers

501

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo

2018 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (10)
Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3Kδ Inhibitor, and Is Required for Functional Activity

2018 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (5)
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ

2017 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (26)
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

2017 European Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (15)
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (22)
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (7)
SAT0370 PI3KΔ Pathway a Novel Therapeutic Target for Sjogren's Syndrome

2015 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Engineering human MEK-1 for structural studies: A case study of combinatorial

2012 Journal of Structural Biology
Show All
- Source
- Cite
- Save
Citations (0)
Differential chemokine activation of CC chemokine receptor 1‐regulated pathways: ligand selective activation of Gα 14‐coupled pathways

2004 European Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (36)
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

2004 Molecular Pharmacology
Show All
- Source
- Cite
- Save
Citations (41)